Takeaways from this week in optometry: May 5 - May 9

Aldeyra Therapeutics has achieved primary end point in one of its phase 3 trials of reproxalap for the treatment of dry eye disease, which the company will include in the resubmission of the new drug application (NDA) for the therapeutic candidate.¹ The dry eye chamber trial was statistically superior to the vehicle in terms of ocular discomfort and while the field trial missed statistical significance for the primary end point, it was consistent with previous field trials and will be submitted with the NDA submission as supportive data. The company intends to resubmit its NDA in mid-2025, pending a Type A meeting with the FDA.